And the cost? The latest cross-sectional analyses peg the annual economic burden between $722.8 billion and $735 billion—exceeding the combined costs of diabetes, cardiovascular disease, and cancer.
The path forward will not come from another cycle of proof-of-concept studies. It will require implementation infrastructure—clinical training that equips providers across disciplines to deliver integrated, team-based care; reimbursement models that reward functional outcomes rather than procedure volume; patient education that builds self-management capacity and shared decision-making; and the systematic integration of behavioral health, physical rehabilitation, and risk mitigation into every pain care pathway. What follows is the evidence base that makes this case unavoidable.
Neuroimaging studies show that chronic pain physically alters brain architecture, disrupting the insular cortex, anterior cingulate cortex, and the brain's endogenous reward and stress regulation systems. These shared neural pathways explain what every clinician managing complex pain patients already suspects: the extraordinarily high comorbidity between chronic pain, depression, anxiety, PTSD, and substance use disorders is not coincidental. It is neurobiological.
Failing to treat chronic pain is not simply allowing discomfort. It is permitting a progressive neurodegenerative process that dismantles psychological resilience.
Demographics and Geography Tell a Story of Structural Inequity
American Indian and Alaska Native adults experience chronic pain at 30.7%, with high-impact chronic pain rates (12.8%) roughly double that of White adults and six times higher than Asian adults. Adults living below the federal poverty level face high-impact chronic pain rates of 14.4% — roughly four times the rate of higher-income populations. The average age of onset has dropped from 42.1 years in 2019 to 34.2 years, meaning younger workers are entering the chronic pain pipeline earlier than ever. Veterans account for a disproportionate share of treatment-resistant cases, with as many as 50% of VHA patients experiencing chronic pain.
Geography compounds all of these disparities, and nowhere is this more evident than across New York State. Rural counties throughout the North Country, Southern Tier, Finger Lakes, and Western New York face acute shortages of pain specialists and interdisciplinary teams, forcing many patients to travel sixty miles or more — or to go without — and placing disproportionate responsibility on Federally Qualified Health Centers that were not originally structured to deliver biopsychosocial pain management at scale. Suburban populations on Long Island, in Westchester, and across the Hudson Valley often have better access to specialists on paper but encounter fragmented, employer-insurance-gated care, with interdisciplinary teams rarely covered as a coordinated unit. Urban corridors — New York City, Buffalo, Rochester, Syracuse, Albany — concentrate both the specialists and the most clinically complex patients, including the 31% of treatment-resistant cases found among military veterans in certain urban areas, yet safety-net hospitals and emergency departments continue to absorb the care that fragmented outpatient systems cannot deliver.
Race, socioeconomic status, geography, occupation, and lived experience all shape both the trajectory and the severity of this disease. The biopsychosocial model is not an academic abstraction — it is the only framework that accounts for these realities.
A New York Opportunity: Settlement Funds as Evidence-Based Abatement
Chronic pain is the upstream clinical driver of the opioid crisis that these settlements were designed to address. An interdisciplinary pain care infrastructure is among the most evidence-based abatement investments a county can make. Concrete deployment opportunities include FQHC-based pain navigation teams supported by the new CMS billing codes, telehealth expansion into underserved rural regions, Medicaid reimbursement parity for non-pharmacological therapies, CBT-for-chronic-pain delivery in primary care settings, community health worker integration into multidisciplinary pain teams, and workforce development for allied pain disciplines.
Every dollar deployed upstream into biopsychosocial pain management is a dollar that reduces downstream ED utilization, surgical revision costs, disability claims, and — most critically — the next generation of substance use disorder cases.
Where the Money Goes — and Where It's Wasted
Much of this spending is structurally inefficient. Chronic pain patients cycle through fragmented primary care encounters, repetitive diagnostics, low-yield imaging, and unwarranted surgical interventions — none of which address central sensitization. Failed back surgery syndrome alone generates billions in revision costs. Emergency departments absorb approximately 40% of all visits from pain patients — roughly 24 million ED encounters per year — despite being fundamentally mismatched to chronic pain management.
Meanwhile, presenteeism erodes productivity long before absenteeism forces patients out of the labor market entirely. And for those who reach the disability system, the subjective nature of pain and the absence of definitive biomarkers make the claims process adversarial, protracted, and psychologically devastating.
The Mental Health Crisis Hiding Inside the Pain Crisis
The substance use connection is equally stark. Research shows that nearly half of polysubstance users experience chronic pain — double the rate seen in non-substance-using populations. Patients with comorbid mood disorders are more likely to be prescribed long-term opioid therapy, creating a clinical paradox where the most vulnerable patients receive the highest-risk interventions.
Treating the addiction without treating the pain is clinical futility. Treating the pain without treating the psychiatric comorbidity is equally incomplete.
The Evidence for Interdisciplinary Care Is Not Ambiguous
Return-to-work rates of 67%, compared to 24% under conventional unimodal treatment. Over 50% resolution of suicidal ideation among participants in structured pain management programs. More than 25,000 patient-months of opioid use were safely avoided within 22 months through interdisciplinary oversight. Net savings of $27,119 per family in the year following intensive rehabilitation. Collective medical savings of $280 million annually compared to conventional care. Workplace productivity gains average $12,600 per successfully treated patient.
The incremental cost per QALY gained in interdisciplinary programs has been estimated at approximately $2,420 — a figure that signals exceptionally high value by any health-economic standard.
These are not marginal improvements. They represent a fundamentally different trajectory for patients, employers, insurers, and the healthcare system.
The VA Got It Right—And Civilian Healthcare Should Follow
The VA's SCOUTT program expands medication-assisted treatment for opioid use disorder within standard clinics, and its naloxone distribution initiative places rescue medication in public AED cabinets. This is not an aspirational policy. It is an operational infrastructure.
Civilian healthcare systems — including New York's Medicaid program, managed care organizations, and county health departments — have no shortage of strategic guidance. The HHS National Pain Strategy and the CDC's 2022 Clinical Practice Guidelines both call for the same biopsychosocial transformation. What is missing is the structural will to implement it.
Moving From Evidence to Operationalization
This is the work that Anodunos was built for. Through the Anodunos Method Navigator (AMN) and Anodunos Method Provider (AMP) certification programs, and in partnership with the U.S. Pain Foundation, we are operationalizing the biopsychosocial model — translating the evidence into clinical workflows, provider training, and patient empowerment frameworks that make interdisciplinary care the standard, not the exception.
The data in this article represent real people — over 60 million nationally and every New Yorker navigating a fragmented system at the county, regional, and state levels. They deserve better. And the evidence says better is achievable.
Nothing About Us, Without Us.
The path forward will not come from another cycle of proof-of-concept studies. It will require implementation infrastructure—clinical training that equips providers across disciplines to deliver integrated, team-based care; reimbursement models that reward functional outcomes rather than procedure volume; patient education that builds self-management capacity and shared decision-making; and the systematic integration of behavioral health, physical rehabilitation, and risk mitigation into every pain care pathway. What follows is the evidence base that makes this case unavoidable.
This Is a Disease, Not a Symptom
The epistemological shift in pain science is settled: chronic pain is a distinct pathological entity, not merely a symptom that resolves when tissue heals. When pain persists beyond three to six months, the nervous system undergoes central sensitization — a state of maladaptive neuroplasticity where ordinarily innocuous stimuli produce pain (allodynia) and painful stimuli are perceived as far more severe than warranted (hyperalgesia).
Neuroimaging studies show that chronic pain physically alters brain architecture, disrupting the insular cortex, anterior cingulate cortex, and the brain's endogenous reward and stress regulation systems. These shared neural pathways explain what every clinician managing complex pain patients already suspects: the extraordinarily high comorbidity between chronic pain, depression, anxiety, PTSD, and substance use disorders is not coincidental. It is neurobiological.
Failing to treat chronic pain is not simply allowing discomfort. It is permitting a progressive neurodegenerative process that dismantles psychological resilience.
Demographics and Geography Tell a Story of Structural Inequity
The burden of chronic pain is not evenly distributed, and the disparities reveal systemic failures in access, detection, and care delivery:
American Indian and Alaska Native adults experience chronic pain at 30.7%, with high-impact chronic pain rates (12.8%) roughly double that of White adults and six times higher than Asian adults. Adults living below the federal poverty level face high-impact chronic pain rates of 14.4% — roughly four times the rate of higher-income populations. The average age of onset has dropped from 42.1 years in 2019 to 34.2 years, meaning younger workers are entering the chronic pain pipeline earlier than ever. Veterans account for a disproportionate share of treatment-resistant cases, with as many as 50% of VHA patients experiencing chronic pain.
Geography compounds all of these disparities, and nowhere is this more evident than across New York State. Rural counties throughout the North Country, Southern Tier, Finger Lakes, and Western New York face acute shortages of pain specialists and interdisciplinary teams, forcing many patients to travel sixty miles or more — or to go without — and placing disproportionate responsibility on Federally Qualified Health Centers that were not originally structured to deliver biopsychosocial pain management at scale. Suburban populations on Long Island, in Westchester, and across the Hudson Valley often have better access to specialists on paper but encounter fragmented, employer-insurance-gated care, with interdisciplinary teams rarely covered as a coordinated unit. Urban corridors — New York City, Buffalo, Rochester, Syracuse, Albany — concentrate both the specialists and the most clinically complex patients, including the 31% of treatment-resistant cases found among military veterans in certain urban areas, yet safety-net hospitals and emergency departments continue to absorb the care that fragmented outpatient systems cannot deliver.
Race, socioeconomic status, geography, occupation, and lived experience all shape both the trajectory and the severity of this disease. The biopsychosocial model is not an academic abstraction — it is the only framework that accounts for these realities.
A New York Opportunity: Settlement Funds as Evidence-Based Abatement
For New York counties, these realities intersect with one of the most consequential public health funding streams in a generation: the New York State Opioid Settlement Fund. Attorney General Letitia James has secured over $3 billion through settlements with opioid manufacturers and distributors, structured as annual payments over 18 years. More than $330 million has already been distributed directly to counties over the past four years, with an additional $157 million designated for regional abatement across FY 2023–2026 under OASAS oversight, allocated to Local Government Units based on population, overdose death rates, and mental health and equity indicators.
Chronic pain is the upstream clinical driver of the opioid crisis that these settlements were designed to address. An interdisciplinary pain care infrastructure is among the most evidence-based abatement investments a county can make. Concrete deployment opportunities include FQHC-based pain navigation teams supported by the new CMS billing codes, telehealth expansion into underserved rural regions, Medicaid reimbursement parity for non-pharmacological therapies, CBT-for-chronic-pain delivery in primary care settings, community health worker integration into multidisciplinary pain teams, and workforce development for allied pain disciplines.
Every dollar deployed upstream into biopsychosocial pain management is a dollar that reduces downstream ED utilization, surgical revision costs, disability claims, and — most critically — the next generation of substance use disorder cases.
Where the Money Goes — and Where It's Wasted
Of the $722.8 billion annual national burden, $530.6 billion is spent on direct medical costs, while $192.2 billion is lost to reduced workplace productivity. At the individual level, chronic pain patients incur $8,068 more in annual medical expenses than those without pain.
Much of this spending is structurally inefficient. Chronic pain patients cycle through fragmented primary care encounters, repetitive diagnostics, low-yield imaging, and unwarranted surgical interventions — none of which address central sensitization. Failed back surgery syndrome alone generates billions in revision costs. Emergency departments absorb approximately 40% of all visits from pain patients — roughly 24 million ED encounters per year — despite being fundamentally mismatched to chronic pain management.
Meanwhile, presenteeism erodes productivity long before absenteeism forces patients out of the labor market entirely. And for those who reach the disability system, the subjective nature of pain and the absence of definitive biomarkers make the claims process adversarial, protracted, and psychologically devastating.
The Mental Health Crisis Hiding Inside the Pain Crisis
Between 35% and 45% of people with chronic pain meet criteria for clinical depression. The lifetime prevalence of suicidal ideation in this population is approximately 20%, and suicide attempt rates range from 5% to 15%. Among Americans who died by suicide, roughly 9% had chronic pain, and more than half of those had at least one additional chronic medical condition.
The substance use connection is equally stark. Research shows that nearly half of polysubstance users experience chronic pain — double the rate seen in non-substance-using populations. Patients with comorbid mood disorders are more likely to be prescribed long-term opioid therapy, creating a clinical paradox where the most vulnerable patients receive the highest-risk interventions.
Treating the addiction without treating the pain is clinical futility. Treating the pain without treating the psychiatric comorbidity is equally incomplete.
The Evidence for Interdisciplinary Care Is Not Ambiguous
Interdisciplinary multimodal pain treatment (IMPT) — coordinated teams of physicians, physical therapists, psychologists, and social workers delivering integrated biopsychosocial care — produces outcomes that fragmented conventional care simply cannot match:
Return-to-work rates of 67%, compared to 24% under conventional unimodal treatment. Over 50% resolution of suicidal ideation among participants in structured pain management programs. More than 25,000 patient-months of opioid use were safely avoided within 22 months through interdisciplinary oversight. Net savings of $27,119 per family in the year following intensive rehabilitation. Collective medical savings of $280 million annually compared to conventional care. Workplace productivity gains average $12,600 per successfully treated patient.
The incremental cost per QALY gained in interdisciplinary programs has been estimated at approximately $2,420 — a figure that signals exceptionally high value by any health-economic standard.
These are not marginal improvements. They represent a fundamentally different trajectory for patients, employers, insurers, and the healthcare system.
The VA Got It Right—And Civilian Healthcare Should Follow
The Veterans Health Administration's Stepped Care Model for Pain Management is arguably the most fully operationalized biopsychosocial pain framework in the country. It embeds Pain Champions and multidisciplinary teams directly within primary care, mandates the broad availability of non-pharmacological modalities (yoga, Tai Chi, acupuncture), integrates addiction medicine and suicide prevention into the pain continuum, and delivers CBT for chronic pain in primary care settings.
The VA's SCOUTT program expands medication-assisted treatment for opioid use disorder within standard clinics, and its naloxone distribution initiative places rescue medication in public AED cabinets. This is not an aspirational policy. It is an operational infrastructure.
Civilian healthcare systems — including New York's Medicaid program, managed care organizations, and county health departments — have no shortage of strategic guidance. The HHS National Pain Strategy and the CDC's 2022 Clinical Practice Guidelines both call for the same biopsychosocial transformation. What is missing is the structural will to implement it.
Moving From Evidence to Operationalization
The research base is mature. The economic case is overwhelming. The chronic pain field does not need more proof-of-concept — it needs the implementation infrastructure outlined at the start of this piece: integrated clinical training, outcome-based reimbursement, patient education empowered, and the systematic integration of behavioral health, physical rehabilitation, and risk mitigation into every pain care pathway.
This is the work that Anodunos was built for. Through the Anodunos Method Navigator (AMN) and Anodunos Method Provider (AMP) certification programs, and in partnership with the U.S. Pain Foundation, we are operationalizing the biopsychosocial model — translating the evidence into clinical workflows, provider training, and patient empowerment frameworks that make interdisciplinary care the standard, not the exception.
The data in this article represent real people — over 60 million nationally and every New Yorker navigating a fragmented system at the county, regional, and state levels. They deserve better. And the evidence says better is achievable.
Nothing About Us, Without Us.
The Anodunos Method
Quick links
Created with
